Research ArticleArticle
Safety of Etanercept and Methotrexate in Patients with Rheumatoid Arthritis and Hepatitis C Virus Infection: A Multicenter Randomized Clinical Trial
Florenzo Iannone, Giovanni La Montagna, Gianfilippo Bagnato, Elisa Gremese, AnnaRita Giardina and Giovanni Lapadula
The Journal of Rheumatology January 2014, jrheum.130658; DOI: https://doi.org/10.3899/jrheum.130658
Florenzo Iannone
From the Interdisciplinary Department of Medicine, Rheumatology Unit, Bari; Rheumatology Unit, II University of Naples, Naples; Rheumatology Unit, Messina; Università Cattolica del Sacro Cuore, Rome; Rheumatology Unit, University of Palermo, Italy. Florenzo Iannone has received consulting fees, speaking fees or honoraria (less than €10,000) from Pfizer, Merck, Abbott, Bristol-Myers Squibb, and UCB. F. Iannone, MD, PhD, Associate Professor of Rheumatology, Interdisciplinary Department of Medicine, Rheumatology Unit, Bari; G. La Montagna, MD, Rheumatology Unit, II University of Naples; G. Bagnato, MD, Rheumatology Unit, Messina; E. Gremese, MD, Università Cattolica del Sacro Cuore; A.R. Giardina, MD, Rheumatology Unit, University of Palermo; G. Lapadula, MD, Interdisciplinary Department of Medicine, Rheumatology Unit, Bari. Address correspondence to Dr. F. Iannone, Interdisciplinary Department of Medicine-Rheumatology Unit, Policlinico, Piazza G. Cesare 11, 70124 Bari, Italy. E-mail: florenzo.iannone@uniba.it. Accepted for publication October 1, 2013.
Giovanni La Montagna
From the Interdisciplinary Department of Medicine, Rheumatology Unit, Bari; Rheumatology Unit, II University of Naples, Naples; Rheumatology Unit, Messina; Università Cattolica del Sacro Cuore, Rome; Rheumatology Unit, University of Palermo, Italy. Florenzo Iannone has received consulting fees, speaking fees or honoraria (less than €10,000) from Pfizer, Merck, Abbott, Bristol-Myers Squibb, and UCB. F. Iannone, MD, PhD, Associate Professor of Rheumatology, Interdisciplinary Department of Medicine, Rheumatology Unit, Bari; G. La Montagna, MD, Rheumatology Unit, II University of Naples; G. Bagnato, MD, Rheumatology Unit, Messina; E. Gremese, MD, Università Cattolica del Sacro Cuore; A.R. Giardina, MD, Rheumatology Unit, University of Palermo; G. Lapadula, MD, Interdisciplinary Department of Medicine, Rheumatology Unit, Bari. Address correspondence to Dr. F. Iannone, Interdisciplinary Department of Medicine-Rheumatology Unit, Policlinico, Piazza G. Cesare 11, 70124 Bari, Italy. E-mail: florenzo.iannone@uniba.it. Accepted for publication October 1, 2013.
Gianfilippo Bagnato
From the Interdisciplinary Department of Medicine, Rheumatology Unit, Bari; Rheumatology Unit, II University of Naples, Naples; Rheumatology Unit, Messina; Università Cattolica del Sacro Cuore, Rome; Rheumatology Unit, University of Palermo, Italy. Florenzo Iannone has received consulting fees, speaking fees or honoraria (less than €10,000) from Pfizer, Merck, Abbott, Bristol-Myers Squibb, and UCB. F. Iannone, MD, PhD, Associate Professor of Rheumatology, Interdisciplinary Department of Medicine, Rheumatology Unit, Bari; G. La Montagna, MD, Rheumatology Unit, II University of Naples; G. Bagnato, MD, Rheumatology Unit, Messina; E. Gremese, MD, Università Cattolica del Sacro Cuore; A.R. Giardina, MD, Rheumatology Unit, University of Palermo; G. Lapadula, MD, Interdisciplinary Department of Medicine, Rheumatology Unit, Bari. Address correspondence to Dr. F. Iannone, Interdisciplinary Department of Medicine-Rheumatology Unit, Policlinico, Piazza G. Cesare 11, 70124 Bari, Italy. E-mail: florenzo.iannone@uniba.it. Accepted for publication October 1, 2013.
Elisa Gremese
From the Interdisciplinary Department of Medicine, Rheumatology Unit, Bari; Rheumatology Unit, II University of Naples, Naples; Rheumatology Unit, Messina; Università Cattolica del Sacro Cuore, Rome; Rheumatology Unit, University of Palermo, Italy. Florenzo Iannone has received consulting fees, speaking fees or honoraria (less than €10,000) from Pfizer, Merck, Abbott, Bristol-Myers Squibb, and UCB. F. Iannone, MD, PhD, Associate Professor of Rheumatology, Interdisciplinary Department of Medicine, Rheumatology Unit, Bari; G. La Montagna, MD, Rheumatology Unit, II University of Naples; G. Bagnato, MD, Rheumatology Unit, Messina; E. Gremese, MD, Università Cattolica del Sacro Cuore; A.R. Giardina, MD, Rheumatology Unit, University of Palermo; G. Lapadula, MD, Interdisciplinary Department of Medicine, Rheumatology Unit, Bari. Address correspondence to Dr. F. Iannone, Interdisciplinary Department of Medicine-Rheumatology Unit, Policlinico, Piazza G. Cesare 11, 70124 Bari, Italy. E-mail: florenzo.iannone@uniba.it. Accepted for publication October 1, 2013.
AnnaRita Giardina
From the Interdisciplinary Department of Medicine, Rheumatology Unit, Bari; Rheumatology Unit, II University of Naples, Naples; Rheumatology Unit, Messina; Università Cattolica del Sacro Cuore, Rome; Rheumatology Unit, University of Palermo, Italy. Florenzo Iannone has received consulting fees, speaking fees or honoraria (less than €10,000) from Pfizer, Merck, Abbott, Bristol-Myers Squibb, and UCB. F. Iannone, MD, PhD, Associate Professor of Rheumatology, Interdisciplinary Department of Medicine, Rheumatology Unit, Bari; G. La Montagna, MD, Rheumatology Unit, II University of Naples; G. Bagnato, MD, Rheumatology Unit, Messina; E. Gremese, MD, Università Cattolica del Sacro Cuore; A.R. Giardina, MD, Rheumatology Unit, University of Palermo; G. Lapadula, MD, Interdisciplinary Department of Medicine, Rheumatology Unit, Bari. Address correspondence to Dr. F. Iannone, Interdisciplinary Department of Medicine-Rheumatology Unit, Policlinico, Piazza G. Cesare 11, 70124 Bari, Italy. E-mail: florenzo.iannone@uniba.it. Accepted for publication October 1, 2013.
Giovanni Lapadula
From the Interdisciplinary Department of Medicine, Rheumatology Unit, Bari; Rheumatology Unit, II University of Naples, Naples; Rheumatology Unit, Messina; Università Cattolica del Sacro Cuore, Rome; Rheumatology Unit, University of Palermo, Italy. Florenzo Iannone has received consulting fees, speaking fees or honoraria (less than €10,000) from Pfizer, Merck, Abbott, Bristol-Myers Squibb, and UCB. F. Iannone, MD, PhD, Associate Professor of Rheumatology, Interdisciplinary Department of Medicine, Rheumatology Unit, Bari; G. La Montagna, MD, Rheumatology Unit, II University of Naples; G. Bagnato, MD, Rheumatology Unit, Messina; E. Gremese, MD, Università Cattolica del Sacro Cuore; A.R. Giardina, MD, Rheumatology Unit, University of Palermo; G. Lapadula, MD, Interdisciplinary Department of Medicine, Rheumatology Unit, Bari. Address correspondence to Dr. F. Iannone, Interdisciplinary Department of Medicine-Rheumatology Unit, Policlinico, Piazza G. Cesare 11, 70124 Bari, Italy. E-mail: florenzo.iannone@uniba.it. Accepted for publication October 1, 2013.
Published eLetters
eLetters are comments published online only and are not peer-reviewed. Publication of eLetter submissions is not guaranteed, and all submissions are reviewed and edited at the discretion of The Journal's staff.
If you wish to publish Letters to the Editor or Correspondence, please submit through our online submission system ScholarOne Manuscripts.
Jump to comment:
No eLetters have been published for this article.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Safety of Etanercept and Methotrexate in Patients with Rheumatoid Arthritis and Hepatitis C Virus Infection: A Multicenter Randomized Clinical Trial
Florenzo Iannone, Giovanni La Montagna, Gianfilippo Bagnato, Elisa Gremese, AnnaRita Giardina, Giovanni Lapadula
The Journal of Rheumatology Jan 2014, jrheum.130658; DOI: 10.3899/jrheum.130658
Safety of Etanercept and Methotrexate in Patients with Rheumatoid Arthritis and Hepatitis C Virus Infection: A Multicenter Randomized Clinical Trial
Florenzo Iannone, Giovanni La Montagna, Gianfilippo Bagnato, Elisa Gremese, AnnaRita Giardina, Giovanni Lapadula
The Journal of Rheumatology Jan 2014, jrheum.130658; DOI: 10.3899/jrheum.130658